Guardant Health, Inc., a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening is now covered for active-duty service members and their families ...

On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.’s (NASDAQ:GH) Shield blood test for colorectal ...

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, ...

Guardant Health says it is the first blood test approved by the FDA as a primary screening option for colorectal cancer. Shield is also the first blood test for colorectal cancer screening that meets ...

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States Collaboration to enable streamlined and ...

For the first time, the U.S. Food and Drug Administration has approved a blood test as a primary screening option for colorectal cancer. Guardant Health's Shield blood test was approved Monday as a ...

Strategic partnership will expand Shield to PathGroup’s 15,000+ primary care and OBGYN physicians PathGroup’s extensive network of phlebotomists and Patient Service Centers enables easier access to ...

Colorectal cancer is the second-leading cause of cancer-related death in the U.S., even though it is highly treatable if caught early.2 The American Cancer Society estimates that more than 150,000 ...

Streamlined access to Guardant Shield ™ will help millions of people residing in senior living facilities to stay up to date on colorectal cancer screening LabFlorida/SunDX will provide patients in ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid Services (CMS) has approved Advanced ...